PET/CT Staging of Head-Neck Cancer Trial On | PET
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
PET PET/CT Staging of Head-Neck Cancer Trial On

PET/CT Staging of Head-Neck Cancer Trial On

Radiology News

PETThe American College of Radiology Imaging Network (ACRIN) recently activated “A Multicenter Trial of FDG-PET-CT Staging of Head and Neck Cancer and its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patient” (ACRIN 6685).

Led by Val Lowe, MD, professor of radiology, Division of Nuclear Medicine, at Mayo Clinic, Rochester, MN, the trial primary aims are to determine the predictive value of FDG-PET-CT for staging the clinically-defined negative neck (N0 neck) based upon pathological sampling of the neck lymph nodes and to determine the potential of FDG-PET-CT to change treatment of the N0 neck patient.

Participants with newly diagnosed head and neck squamous cell carcinoma will undergo a FDG-PET-CT scan prior to surgical resection. The surgeon will have access to the FDG-PET-CT results prior to the surgical procedure.  The data will demonstrate how the inclusion of the FDG-PET-CT imaging will affect the determination of extent of disease, disease characterization and prognosis, and the surgical plan originally devised from clinical nodal assessment and CT or MRI results.

Quality of life assessments and cost effectiveness analysis will be included in the study to determine the impact of FDG-PET-CT inclusion relative to treatment of the N0 neck. Prior to imaging, blood samples will be collected to explore serum biomarkers as they correspond to prognosis, staging, and FDG-PET-CT findings. A correlation between FDG-PET-CT imaging and biomarker data in the same patient group would be useful for early disease detection and to decrease treatment costs.

Ultimately, the study is expected to confirm that FDG-PET-CT images improve the characterization of the N0 neck by accurately diagnosing NO necks, better defining extent of primary disease, discovering unappreciated distant metastasis, reducing morbidity, and representing value to society. Up to 15 participating sites are expected to accrue 292 study participants in approximately two years.

Source: ACR

Discuss more about PET in the PET user group.

 

Related Articles